Cypress Bioscience (CYPB) Says Phase IIa Trials Don't Support Continuing Development Program to Evaluate Combinations of Mirtazapine
Tweet Send to a Friend
Cypress Bioscience Inc. (NASDAQ: CYPB) announced that results of recently completed Phase IIa trials do not support continuing a development ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
